middl
east
respiratori
syndrom
mer
deadli
viral
respiratori
diseas
caus
merscoronaviru
merscov
infect
date
specif
treatment
proven
effect
viral
diseas
addit
vaccin
licens
prevent
merscov
infect
thu
far
therefor
current
review
focus
recent
studi
search
effect
mer
vaccin
overal
vaccin
candid
merscov
mainli
base
upon
viral
spike
protein
due
vital
role
viral
infect
although
sever
studi
focus
viral
protein
nucleocapsid
n
protein
envelop
e
protein
nonstructur
protein
also
report
gener
potenti
vaccin
candid
classifi
six
type
viral
vectorbas
vaccin
dna
vaccin
subunit
vaccin
nanoparticlebas
vaccin
inactivatedwhol
viru
vaccin
liveattenu
vaccin
discuss
detail
besid
immun
respons
potenti
antibodi
depend
enhanc
merscov
infect
extens
review
addit
anim
model
use
studi
merscov
evalu
vaccin
candid
discuss
intens
camel
flu
commonli
known
middl
east
respiratori
syndrom
mer
respiratori
diseas
caus
merscoronaviru
merscov
merscov
first
identifi
saudi
arabia
februari
countri
worldwid
report
case
merscov
infect
report
viral
infect
associ
death
correspond
fatal
identifi
case
world
health
organ
although
actual
fatal
rate
viral
infect
like
due
unidentifi
mild
asymptomat
case
major
case
occur
saudi
arabia
amount
report
case
associ
death
fatal
world
health
organ
major
identifi
merscov
case
nosocomi
acquir
via
direct
close
contact
infect
patient
chowel
et
al
cauchemez
et
al
wherea
case
zoonot
transmiss
dromedari
camel
human
report
primarili
saudi
arabia
humancamel
interact
frequent
gossner
et
al
hitherto
specif
treatment
vaccin
avail
merscov
infect
although
merscov
current
list
potenti
pandem
threat
recent
outbreak
south
korea
demonstr
viru
emerg
second
third
gener
contact
immedi
rais
concern
multipl
mutat
merscov
might
caus
enhanc
humantohuman
transmiss
wang
et
al
oh
et
al
recent
merscov
ad
niaid
pathogen
prioriti
list
categori
c
prioriti
pathogen
due
potenti
applic
biolog
warfar
du
et
al
prevent
measur
merscov
infect
particularli
vaccin
develop
crucial
avoid
deadli
unexpect
futur
pandem
middl
east
respiratori
syndromecoronaviru
caus
agent
mer
posit
sens
singlestrand
rna
betacoronaviru
belong
famili
coronavirida
viral
genom
kb
length
flank
cap
tail
scobey
et
al
merscov
genom
contain
least
open
read
frame
orf
encod
structur
protein
spike
protein
envelop
e
protein
membran
protein
nucleocapsid
n
protein
nonstructur
protein
accessori
protein
du
et
al
viral
protein
n
protein
particular
interest
develop
vaccin
merscov
although
protein
e
protein
potenti
immunogen
live
attenu
vaccin
almazan
et
al
menacheri
et
al
two
viral
protein
merscov
n
protein
demonstr
highli
immunogen
capabl
elicit
tcell
respons
howev
protein
shown
induc
neutral
antibodi
critic
effector
merscov
notabl
n
protein
also
propos
potenti
protect
immunogen
neutral
antibodi
tcell
immun
respons
silico
approach
shi
et
al
despit
predict
biolog
data
present
thu
far
anoth
potenti
b
cell
epitop
merscov
e
protein
identifi
recent
use
silico
method
yet
similarli
biolog
data
present
xie
et
al
therefor
merscov
vaccin
candid
still
base
full
length
part
protein
ideal
effect
merscov
vaccin
requir
induc
robust
humor
cellmedi
immun
particularli
antibodi
respons
crucial
surviv
vaccin
host
du
et
al
previou
studi
indic
level
serum
neutral
antibodi
correl
posit
reduct
lung
pathogenesi
increas
surviv
anim
challeng
merscov
zhang
et
al
gener
potenti
merscov
vaccin
candid
abl
elicit
system
antibodi
respons
produc
high
titer
serum
igg
upon
immun
mani
fail
gener
suffici
mucos
immun
unless
vaccin
administ
via
mucos
intranas
rout
activ
mucos
immun
heavili
depend
rout
immun
common
challeng
vaccin
develop
mani
respiratori
pathogen
et
al
guo
et
al
preexist
neutral
mucos
antibodi
import
first
line
defens
merscov
infect
neutral
antibodi
elicit
vaccin
base
protein
could
bind
receptor
bind
domain
rbd
protein
therebi
inhibit
viral
intern
membran
fusion
du
et
al
littl
known
memori
bcell
respons
merscov
apart
recent
studi
demonstr
persist
antimerscov
antibodi
mer
survivor
month
payn
et
al
hand
antibodi
respons
anoth
close
relat
coronaviru
sarscov
persist
wherebi
followup
studi
detect
memori
bcell
respons
sar
survivor
tang
et
al
like
bcell
differenti
merscovspecif
memori
bcell
follow
infect
vaccin
longev
protect
efficaci
memori
bcell
merscov
infect
rechalleng
remain
unresolv
question
du
et
al
perlman
vijay
tcell
respons
elicit
merscov
vaccin
also
play
import
role
protect
mer
support
fact
viral
clearanc
imposs
tcell
defici
mice
possibl
mice
lack
bcell
although
tcell
demonstr
critic
effector
acut
viral
clearanc
protect
subsequ
merscov
infect
larg
mediat
humor
immun
sever
anim
studi
also
demonstr
activ
tcell
respons
follow
immun
merscov
vaccin
candid
result
elev
secret
cytokin
lan
et
al
et
al
malczyk
et
al
muthumani
et
al
also
noteworthi
mention
adjuv
could
coadminist
merscov
vaccin
tailor
possibl
enhanc
immun
respons
elicit
vaccin
one
studi
indic
coadministr
merscov
vaccin
base
protein
alum
mice
result
bias
immun
wherea
robust
mix
immun
respons
produc
addit
adjuv
cysteinephosphateguanin
cpg
oligodeoxynucleotid
odn
includ
formul
lan
et
al
date
detail
investig
merscov
vaccineinduc
memori
tcell
respons
report
howev
merscov
infect
shown
induc
memori
tcell
respons
mer
survivor
least
month
littl
understand
biolog
function
memori
tcell
like
contribut
direct
viru
inhibit
via
cytokin
product
particularli
enhanc
effector
function
tcell
bcell
macleod
et
al
although
subsequ
merscov
infect
gener
antibodi
mediat
memori
cell
believ
facilit
viru
clearanc
elimin
infect
cell
kaech
ahm
zhao
et
al
mer
survivor
later
demonstr
strong
virusspecif
memori
tcell
respons
also
shown
experi
mitig
morbid
hospit
period
similarli
import
tcell
respons
sarscov
also
highlight
mani
studi
channappanavar
et
al
chu
h
et
al
zhao
et
al
interestingli
unlik
sarscov
merscov
infect
cell
human
result
downregul
induc
intrins
extrins
caspasedepend
apoptosi
cell
may
lead
sever
immunopatholog
chu
et
al
addit
chu
et
al
demonstr
capabl
merscov
infect
cell
common
marmoset
critic
potenti
merscov
vaccin
induc
robust
humor
cellmedi
immun
although
protect
merscov
mainli
mediat
humor
immun
tcell
respons
crucial
acut
viral
clearanc
mucos
rout
recommend
merscov
vaccin
deliveri
induc
mucos
immun
addit
system
respons
persist
virusspecif
antibodi
induc
merscov
vaccin
thoroughli
studi
repres
major
challeng
effect
merscov
vaccin
also
requir
induc
immunolog
memori
provid
longliv
protect
turn
reduc
need
booster
long
run
bring
cost
vaccin
lastli
differ
adjuv
may
also
use
improv
immunogen
merscov
vaccin
would
requir
detail
studi
interact
ensur
optim
vaccin
efficaci
safeti
far
three
potenti
merscov
vaccin
dna
vaccin
two
viral
vectorbas
vaccin
advanc
clinic
trial
nation
institut
health
nih
nih
antibodi
depend
enhanc
ade
condit
wherebi
nonneutr
antibodi
produc
follow
infect
vaccin
enhanc
infect
subsequ
infect
kuzmina
et
al
ade
viral
infect
report
dengu
viru
human
immunodefici
viru
influenza
viru
alpha
flavivirus
sarscov
ebola
viru
dutri
et
al
kuzmina
et
al
thu
ade
critic
issu
consid
serious
design
merscov
vaccin
attribut
taxonom
structur
similar
sarscov
merscov
process
involv
develop
new
vaccin
two
virus
larg
extent
similar
vaccin
candid
sarscov
initi
develop
base
fulllength
protein
howev
vaccin
later
demonstr
induc
nonneutr
antibodi
prevent
merscov
infect
immun
anim
protect
viral
challeng
instead
experienc
advers
effect
like
enhanc
hepat
increas
morbid
stronger
inflammatori
respons
weingartl
et
al
czub
et
al
mani
potenti
vaccin
merscov
also
mainli
focus
fulllength
protein
rais
safeti
concern
practic
applic
vaccin
du
et
al
date
ade
observ
merscov
inde
ade
sarscov
infect
human
cell
discov
year
viru
first
identifi
yip
et
al
jaum
et
al
demonstr
nonneutr
antibodi
induc
fulllength
protein
sarscov
facilit
viral
entri
host
cell
via
pathway
understand
merscov
rel
lesser
compar
sarscov
mainli
due
fact
former
discov
less
year
thu
unsurpris
ade
merscov
yet
report
du
et
al
nevertheless
employ
appropri
strategi
method
ade
merscov
infect
could
reveal
futur
two
approach
suggest
mitig
advers
effect
ade
first
approach
involv
shield
nonneutr
epitop
protein
glycosyl
wherea
second
approach
name
immunofocus
aim
direct
adapt
immun
respons
target
critic
neutral
epitop
elicit
robust
protect
immun
du
et
al
okba
et
al
support
evid
latter
merscov
vaccin
candid
base
shorter
domain
induc
slightli
stronger
neutral
activ
base
fulllength
protein
addit
vaccin
candid
base
even
shorter
rbd
induc
highest
neutral
immun
respons
okba
et
al
anim
model
avail
evalu
merscov
vaccin
highli
limit
thu
repres
huge
challeng
vaccin
develop
merscov
infect
human
nonhuman
primatesrhesu
macaqu
munster
et
al
marmoset
falzarano
et
al
dromedari
camel
alagaili
et
al
chu
dk
et
al
memish
et
al
first
anim
model
adopt
develop
merscov
vaccin
rhesu
macaqu
munster
et
al
demonstr
clinic
symptom
merscov
infect
includ
increas
respiratori
rate
bodi
temperatur
hunch
postur
piloerect
cough
reduc
food
intak
radiograph
imag
analysi
also
reveal
vari
degre
pulmonari
diseas
follow
infect
although
viral
rna
merscov
detect
respiratori
tissu
viral
tropism
restrict
primarili
lower
respiratori
tract
rhesu
macaqu
infect
merscov
experienc
transient
mild
moder
diseas
sever
van
doremalen
munster
du
et
al
noteworthi
patholog
chang
induc
rhesu
macaqu
infect
merscov
result
host
inflammatori
respons
trigger
viru
instead
direct
viral
cytolyt
activ
prescott
et
al
common
marmoset
anoth
frequent
use
anim
model
evalu
merscov
vaccin
falzarano
et
al
similar
rhesu
macaqu
humor
cellmedi
immun
could
detect
anim
follow
merscov
vaccin
common
marmoset
infect
merscov
develop
moder
sever
acut
pneumonia
increas
viral
load
respiratori
tract
addit
clinic
symptom
experienc
rhesu
macaqu
van
doremalen
munster
yu
et
al
intriguingli
common
marmoset
also
demonstr
sign
renal
damag
human
case
follow
merscov
infect
viral
rna
could
detect
nonrespiratori
organ
contrari
rhesu
macaqu
van
doremalen
munster
yeung
et
al
falzarano
et
al
also
report
common
marmoset
could
serv
partial
lethal
anim
model
similarli
chan
et
al
demonstr
marmoset
challeng
merscov
develop
sever
diseas
lead
fatal
thereaft
marmoset
success
use
moder
sever
model
studi
merscov
basel
et
al
yeung
et
al
chen
et
al
van
doremalen
et
al
yu
et
al
de
wit
et
al
dromedari
camel
serv
natur
reservoir
merscov
respons
zoonot
transmiss
viru
human
mild
clinic
symptom
increas
bodi
temperatur
rhinorrhea
observ
dromedari
camel
infect
merscov
adney
et
al
interest
merscov
tropism
dromedari
camel
limit
upper
respiratori
tract
less
appar
lower
respiratori
tract
contrari
rhesu
macaqu
adney
et
al
viral
rna
merscov
detect
respiratori
tract
lymph
node
excret
breath
infect
dromedari
camel
viral
shed
upper
respiratori
tract
dromedari
camel
may
explain
effici
viru
transmiss
among
camel
camel
human
adney
et
al
dromedari
camel
immun
mersvcov
vaccin
also
shown
activ
bcell
tcell
respons
muthumani
et
al
haagman
et
al
adney
et
al
although
camel
natur
reservoir
merscov
whilst
macaqu
marmoset
close
relat
human
handl
larg
mammal
labori
costli
lack
small
anim
model
initi
screen
potenti
vaccin
candid
greatli
hamper
develop
merscov
vaccin
unlik
sarscov
merscov
readili
infect
smaller
rodent
mice
hamster
due
substanti
differ
viral
bind
receptor
dipeptidyl
peptidas
goldstein
weiss
nevertheless
consider
amount
effort
devot
produc
merscovpermiss
small
rodent
evalu
merscov
vaccin
mice
transduc
viral
vector
express
human
shown
suscept
merscov
infect
manifest
develop
pneumonia
histopatholog
chang
lung
howev
viral
clearanc
infect
mice
observ
postinfect
fail
recapitul
sever
human
diseas
later
establish
transgen
mous
model
express
global
develop
first
lethal
anim
model
avail
evalu
merscov
vaccin
mortal
note
mice
within
day
postinfect
viru
dissemin
organ
observ
except
high
titer
detect
lung
brain
agraw
et
al
recent
transgen
mous
model
produc
replac
fulllength
mous
gene
human
equival
howev
transgen
mice
demonstr
sign
diseas
follow
merscov
infect
viru
dissemin
organ
observ
pascal
et
al
also
previous
employ
sensit
mice
merscov
infect
substitut
two
amino
acid
posit
mous
although
genet
engin
mice
allow
viral
replic
lung
experi
appar
morbid
follow
infect
wildtyp
merscov
sever
diseas
observ
mice
infect
mouseadapt
merscov
gener
via
serial
lung
passag
cockrel
et
al
mous
vital
normal
glucos
homeostasi
immun
alter
mous
could
unforeseen
complic
mous
model
fan
et
al
therefor
anoth
transgen
mous
model
introduc
gene
insert
genom
locu
use
technolog
mous
model
name
infect
merscov
low
dose
develop
sever
lung
diseas
relat
acut
respiratori
symptom
ard
central
nervou
system
cn
addit
also
suscept
infect
merscov
pseudoviru
serv
altern
test
merscov
vaccin
absenc
facil
fan
et
al
anim
model
describ
summar
tabl
apart
mous
model
rabbit
also
report
asymptomat
infect
merscov
extens
research
anim
could
repres
anoth
potenti
anim
model
evalu
merscov
vaccin
haagman
et
al
smaller
anim
model
econom
avail
vaccin
evalu
addit
eas
anim
manipul
readili
avail
method
test
vaccin
efficaci
sarscov
merscov
coronavirus
known
caus
sever
diseas
human
develop
sar
vaccin
mainli
focus
protein
sarscov
bukreyev
et
al
weingartl
et
al
yang
et
al
czub
et
al
kam
et
al
lin
et
al
fett
et
al
date
vaccin
licens
prevent
merscov
infect
although
sever
vaccin
candid
current
clinic
trial
mani
still
remain
preclin
stage
current
approach
anim
manifest
clinic
sign
within
h
follow
infect
includ
increas
respiratori
rate
bodi
temperatur
hunch
postur
piloerect
cough
reduc
food
intak
vari
degre
pneumonia
mortal
observ
infect
anim
throughout
studi
increas
white
blood
cell
count
earli
transient
viralload
report
higher
lower
respiratori
tract
decreas
overtim
rhesu
macaqu
anim
experienc
earli
increas
neutrophil
postinfect
pi
restor
pi
develop
pneumonia
anim
rapid
infect
shortliv
mortal
viru
dissemin
nonrespiratori
tissu
observ
infect
anim
infect
restrict
primarili
lower
respiratori
tract
genet
closer
human
recapitul
sever
diseas
human
expens
model
due
high
husbandri
requir
de
wit
et
al
rectal
temperatur
anim
increas
day
pi
restor
thereaft
extens
lung
lesion
vari
degre
inflamm
observ
lung
anim
collect
pi
patholog
chang
infect
lung
includ
interstiti
pneumonia
pulmonari
edema
hemorrhag
degener
necrosi
pneumocyt
bronchial
epitheli
cell
sign
damag
nonrespiratori
organ
observ
immunosuppress
rhesu
macaqu
immunosuppress
anim
develop
rapid
pneumonia
less
sever
nonimmunosuppress
monkey
higher
viral
load
viral
shed
viru
dissemin
nonrespiratori
organ
observ
immunosuppress
anim
follow
infect
potenti
model
mimick
merscov
infect
immunocompromis
patient
expens
model
due
high
husbandri
requir
addit
treatment
requir
produc
immunosuppress
anim
prescott
et
al
common
marmoset
infect
anim
develop
progress
sever
pneumonia
character
interstiti
infiltr
anim
euthan
diseas
sever
extens
lung
lesion
observ
infect
anim
differ
necropsi
time
point
viral
rna
could
detect
blood
respiratori
organ
nonrespiratori
organ
includ
kidney
suggest
viru
dissemin
sever
partial
lethal
anim
model
abl
manifest
renal
damag
expens
model
due
high
husbandri
requir
falzarano
et
al
common
marmoset
infect
anim
develop
sever
pneumonia
pi
character
exud
patholog
chang
widespread
pulmonari
edema
hemorrhag
huge
number
inflammatori
cell
yu
et
al
common
marmoset
vitro
analysi
use
lung
kidney
cell
show
hyperexpress
induc
merscov
led
immens
apoptot
respons
gener
iwv
vaccin
rapid
approach
vaccin
product
follow
new
outbreak
howev
use
iwv
vaccin
mer
report
associ
hypersensitivitytyp
lung
immunopatholog
reaction
mous
model
agraw
et
al
therebi
limit
potenti
subunit
vaccin
far
popular
method
develop
mer
vaccin
mostli
focus
recombin
rbd
protein
produc
heterolog
express
system
subunit
vaccin
howev
often
administ
along
adjuv
boost
immunogen
recombin
antigen
nanoparticl
vlpsbase
vaccin
similar
subunit
vaccin
specif
viral
protein
express
unlik
subunit
vaccin
vlpsbase
vaccin
compris
recombin
viral
protein
capabl
selfassembl
larger
particl
resembl
virus
although
immunogen
vlpsbase
vaccin
could
enhanc
adjuv
vlp
serv
adjuv
increas
immunogen
display
epitop
particularli
smaller
one
murata
et
al
quan
et
al
live
attenu
vaccin
compos
live
virus
modifi
remov
reduc
virul
type
vaccin
often
immunogen
wherebi
singl
administr
without
adjuv
suffici
induc
protect
immun
howev
risk
revers
virul
viru
limit
usag
mer
vaccin
viral
vectorbas
vaccin
one
popular
approach
develop
mer
vaccin
two
three
candid
vaccin
enter
clinic
phase
viral
vector
vaccin
approach
util
wellstudi
viru
replic
system
display
merscov
antigen
therebi
induc
protect
immun
merscov
anoth
candid
vaccin
current
phase
iii
clinic
trial
dna
vaccin
unlik
type
vaccin
dna
vaccin
product
involv
viru
replic
protein
express
purif
therefor
reduc
cost
product
howev
administr
dna
vaccin
often
requir
extern
devic
electropor
gene
gun
eventu
increas
cost
immun
tabl
summar
vaccin
candid
merscov
infect
discuss
intens
follow
section
viralvector
encod
protein
im
immun
construct
express
fusion
protein
offer
complet
protect
transgen
mice
merscov
challeng
prevent
pulmonari
perivascular
hemorrhag
dna
encod
protein
im
dna
encod
protein
elicit
stronger
antibodi
cellular
immun
respons
mice
encod
protein
dna
encod
protein
induc
neutral
antibodi
crossreact
merscov
strain
human
camel
origin
dna
encod
protein
im
immun
dna
encod
protein
passiv
transfer
immun
sera
vaccin
mice
protect
merscov
infect
frontier
microbiolog
wwwfrontiersinorg
recombin
rbd
im
sc
subunit
vaccin
administ
togeth
combin
alum
cpg
odn
optim
rbdspecif
humor
cellular
immun
elict
robust
rbdspecif
antibodi
tcell
respons
induc
mice
immun
vaccin
combin
ifa
cpg
odn
low
level
neutral
antibodi
induc
frontier
microbiolog
wwwfrontiersinorg
first
viral
vectorbas
vaccin
report
moss
et
al
develop
potenti
hepat
b
vaccin
use
vaccinia
viral
vector
unlik
subunit
inactiv
vaccin
gener
function
extracellular
antigen
viral
vector
work
carri
dna
encod
immunogen
compon
host
cell
follow
intracellular
antigen
express
therebi
activ
broad
spectrum
cellmedi
immun
addit
humor
immun
respons
major
viralvector
base
vaccin
requir
adjuv
optimum
efficaci
ura
et
al
adenoviru
modifi
vaccinia
viru
ankara
mva
two
common
viral
vector
use
develop
merscov
vaccin
mice
immun
intramuscularli
recombin
human
adenovir
type
vector
encod
fulllength
protein
shown
induc
system
neutral
antibodi
mucos
tcell
immun
intriguingli
mucos
tcell
respons
detect
vaccin
administ
via
intragastr
rout
contrari
previou
find
suggest
import
mucos
vaccin
activ
mucos
immun
recombin
human
adenoviru
type
vector
encod
shorter
extracellular
domain
protein
report
elicit
slightli
stronger
neutral
antibodi
respons
encod
fulllength
suggest
effect
immunofocus
kim
et
al
recent
studi
hashem
et
al
demonstr
construct
express
fusion
protein
offer
complet
protect
transgen
mice
merscov
challeng
prevent
pulmonari
perivascular
hemorrhag
addit
jung
et
al
show
heterolog
primeboost
vaccin
protein
alumadjuv
recombin
protein
nanoparticl
success
induc
immun
respons
specificpathogenfre
balbc
mice
preexist
immun
human
adenoviru
human
popul
widespread
hamper
clinic
applic
vector
vaccin
develop
faustherbovendo
kobing
recent
develop
new
adenoviru
vector
vaccin
antigen
deliveri
focu
serotyp
human
popul
less
expos
chimpanze
adenoviru
repres
attract
altern
human
adenovir
vector
due
good
safeti
profil
lack
preexist
immun
human
popul
dick
et
al
sinc
employ
vaccin
develop
merscov
infect
recombin
encod
fulllength
protein
mer
shown
immunogen
mice
lethal
viru
challeng
use
transgen
mous
model
demonstr
high
protect
efficaci
merscov
alharbi
et
al
munster
et
al
noteworthi
immunogen
protein
could
improv
insert
gene
encod
signal
peptid
human
tissu
plasminogen
activ
tpa
upstream
gene
merscov
mva
vector
alharbi
et
al
current
candid
merscov
vaccin
known
contain
encod
protein
merscov
phase
clinic
trial
trial
estim
complet
decemb
safeti
immunogen
differ
dosag
studi
healthi
adult
volunt
recruit
sponsor
univers
oxford
unit
kingdom
nation
institut
health
nih
recombin
mva
encod
fulllength
protein
repres
anoth
potenti
merscov
vaccin
candid
due
good
safeti
profil
decent
immunogen
high
protect
efficaci
merscov
song
et
al
volz
et
al
alharbi
et
al
anoth
candid
vaccin
current
phase
clinic
trial
mvamerss
trial
perform
univers
medic
center
hamburgeppendorf
germani
safeti
immunogen
mvamerss
healthi
adult
volunt
assess
nation
institut
health
nih
apart
protein
highli
conserv
n
protein
merscov
insert
mva
inocul
mice
although
recombin
mva
encod
nprotein
elicit
tcell
respons
immun
mice
protect
efficaci
investig
veit
et
al
apart
adenoviru
mva
newcastl
diseas
viru
ndv
also
use
viralvector
display
merscov
protein
ndvbase
vaccin
candid
induc
neutral
antibodi
balbc
mice
bactrian
camel
although
viral
vectorbas
vaccin
abl
induc
robust
immun
respons
free
drawback
includ
preexist
immun
viral
vector
risk
pathogenesi
low
viral
titer
product
potenti
tumorigenesi
ura
et
al
dna
vaccin
compos
recombin
plasmid
encod
immunogen
vaccin
typic
deliv
via
direct
inject
gene
gun
electropor
host
cell
immunogen
express
prime
immun
system
ferraro
et
al
dna
vaccin
offer
two
distinct
advantag
subunit
proteinbas
vaccin
eas
dna
manipul
low
cost
product
leitner
et
al
similarli
dna
vaccin
develop
merscov
target
protein
shorter
domain
merscov
dna
encod
fulllength
protein
shown
induc
neutral
antibodi
robust
cellmedi
immun
mice
macaqu
camel
immun
macaqu
challeng
merscov
characterist
clinic
symptom
includ
pneumonia
mitig
muthumani
et
al
one
three
candid
vaccin
current
clinic
trial
sponsor
geneon
life
scienc
inc
korea
phase
clinic
trial
test
vaccin
safeti
profil
human
volunt
complet
walter
reed
armi
institut
research
unit
state
nation
institut
health
nih
current
phase
phase
ii
clinic
trial
perform
intern
vaccin
institut
korea
evalu
safeti
immunogen
well
devic
electropor
cellectra
r
electropor
nation
institut
health
nih
avoid
possibl
advers
effect
induc
fulllength
protein
research
reveal
immun
dna
encod
domain
passiv
transfer
immun
sera
vaccin
mice
protect
merscov
infect
chi
et
al
dna
encod
domain
also
demonstr
superior
encod
fulllength
protein
elicit
antibodi
cellular
respons
dna
encod
protein
shown
induc
neutral
antibodi
crossreact
merscov
strain
human
camel
origin
alamri
et
al
despit
effect
dna
vaccin
spontan
plasmid
integr
host
genom
repres
potenti
risk
probabl
extrem
low
ledwith
et
al
gener
subunit
vaccin
highest
safeti
profil
among
current
vaccin
despit
low
immunogen
du
et
al
precaut
taken
develop
merscov
vaccin
base
protein
avoid
induct
nonneutr
antibodi
unlik
fulllength
protein
rbd
merscov
compris
critic
neutral
domain
lack
nonneutr
immunodomin
region
therefor
upon
immun
rbdbase
vaccin
restrict
produc
rbdspecif
neutral
immun
respons
thu
incap
induc
nonneutr
antibodi
may
potenti
contribut
harm
patholog
effect
du
jiang
wang
et
al
safeti
effect
perspect
rbd
promis
candid
develop
merscov
vaccin
fulllength
protein
rbd
merscov
report
induc
neutral
antibodi
multipl
strain
merscov
due
presenc
sever
conform
neutral
epitop
du
et
al
merscov
strain
singl
mutat
epitop
may
suffic
escap
rbdspecif
neutral
antibodi
wang
et
al
demonstr
amino
acid
mutat
posit
aspart
acid
glycin
substitut
rbd
render
mutat
strain
resist
neutral
rbdspecif
monoclon
antibodi
suscept
anoth
rbdspecif
monoclon
antibodi
antibodi
could
bind
differ
region
rbd
merscov
similarli
rbd
sarscov
also
consist
multipl
neutral
domain
capabl
induc
broad
neutral
immun
respons
mani
sarscov
strain
et
al
develop
antibodi
escap
mutant
may
requir
mutat
two
epitop
rbd
merscov
less
like
take
place
develop
may
exhibit
reduc
viral
fit
tang
et
al
tai
et
al
demonstr
merscov
protein
adjuv
protect
transgen
mice
lethal
merscov
challeng
protect
correl
well
neutral
antibodi
titer
wang
et
al
addit
adjuv
recombin
protein
advax
hcxl
adjuv
sigman
adjuv
system
reduc
delay
viru
shed
upper
respiratori
tract
dromedari
camel
merscov
anim
reservoir
provid
complet
protect
alpaca
surrog
infect
model
merscov
challeng
adney
et
al
gener
merscov
subunit
vaccin
base
domain
requir
use
adjuv
fusion
immun
enhanc
heighten
immunogen
sever
studi
indic
rbd
fuse
fc
fragment
human
igg
rbdfc
elicit
strong
system
neutral
antibodi
cellular
immun
respons
vaccin
mice
du
et
al
et
al
tang
et
al
nyon
et
al
new
zealand
white
rabbit
et
al
immun
rbdfc
also
protect
viral
challeng
et
al
adjuv
freund
adjuv
alum
monophosphoryl
lipid
montanid
also
report
improv
immunogen
protect
rbdfc
mice
particularli
superior
among
adjuv
zhang
et
al
addit
coadministr
multipl
adjuv
togeth
rbd
antigen
could
synergist
improv
immunogen
rbdbase
subunit
vaccin
mice
immun
rbd
antigen
togeth
alum
cpg
odn
produc
stronger
humor
cellular
immun
respons
immun
rbd
antigen
alum
cpg
odn
alon
lan
et
al
rbdbase
subunit
vaccin
also
previous
test
rhesu
macaqu
model
presenc
alum
vaccin
formul
shown
induc
robust
sustain
humor
cellular
immun
partial
protect
rhesu
macaqu
viral
challeng
nativ
spike
merscov
exist
form
trimer
vaccin
design
mimick
nativ
viral
protein
also
report
tai
et
al
pallesen
et
al
use
foldon
fd
fibritin
trimer
domain
pallesen
et
al
synthes
recombin
prefus
trimer
merscov
protein
induc
high
titer
neutral
antibodi
balbcj
mice
similarli
tai
et
al
express
rbd
trimer
fd
demonstr
vaccin
protect
efficaci
surviv
transgen
mice
lethal
merscov
challeng
although
subunit
vaccin
studi
focus
rbd
protein
recent
studi
jiam
et
al
propos
use
recombin
ntermin
domain
rntd
protein
anoth
potenti
vaccin
candid
rntd
use
immun
balbc
mice
induc
neutral
antibodi
reduc
respiratori
tract
patholog
mice
nonleth
merscov
challeng
apart
focus
protein
multival
vaccin
design
use
silico
method
contain
b
cell
cell
epitop
e
n
nsp
propos
srivastava
et
al
howev
biolog
data
present
multival
vaccin
addit
n
protein
domain
protein
conserv
among
coronavirus
repres
attract
target
develop
broadspectrum
coronaviru
vaccin
schindewolf
menacheri
nevertheless
crucial
ensur
protein
contribut
ade
merscov
infect
viruslik
particl
nanoscal
particl
similar
nativ
viral
particl
devoid
infecti
genet
materi
compos
repetit
viral
structur
protein
inher
selfassembl
properti
vlp
nonrepl
noninfecti
vlp
produc
express
viral
structur
protein
suitabl
express
system
yong
et
al
b
ong
et
al
gener
vlpsbase
vaccin
similar
whole
inactiv
viru
vaccin
requir
viral
inactiv
step
may
alter
antigen
immunogen
viral
protein
live
viru
involv
manufactur
process
vlp
easili
gener
lowcontain
manufactur
environ
dezur
et
al
viruslik
particl
merscov
previous
produc
baculovir
express
system
coexpress
e
protein
merscov
vlp
gener
indistinguish
authent
viral
particl
observ
electron
microscop
vlp
administ
alum
induc
neutral
antibodi
immun
rhesu
macaqu
wang
et
al
intriguingli
protein
merscov
express
alon
selfassembl
nanoparticl
approxim
nm
quarter
diamet
authent
viral
particl
immunogen
studi
mice
demonstr
nanoparticl
elicit
antibodi
respons
presenc
alum
adjuv
replac
matrix
adjuv
induc
significantli
higher
titer
neutral
antibodi
coleman
et
al
viral
challeng
immun
matrix
protein
nanoparticl
proven
protect
efficaci
vaccin
formul
merscov
mention
earlier
viral
vectorbas
vaccin
adjuv
protein
nanoparticl
booster
mice
prime
also
yield
promis
immun
respons
jung
et
al
advanc
genet
engin
enabl
vlp
display
differ
epitop
virus
produc
chimer
vlp
cvlp
ong
et
al
express
rbd
merscov
fuse
structur
protein
canin
parvoviru
cpv
produc
cvlp
display
rbd
merscov
cvlp
morpholog
similar
nativ
cpv
elicit
rbdspecif
humor
cellmedi
immun
mice
wang
et
al
cvlp
display
protein
merscov
matrix
protein
influenza
viru
also
develop
shown
immunogen
mous
model
howev
actual
protect
efficaci
cvlp
merscov
yet
investig
vivo
addit
vaccin
base
vlp
nonvir
nanoparticl
ferritin
also
report
potenti
carrier
merscov
antigen
kim
et
al
util
chapernamedi
ferritin
nanoparticl
display
merscov
rbd
adjuv
ferritinbas
nanoparticl
induc
rbdspecif
antibodi
balbc
mice
inhibit
rbd
bind
receptor
protein
suggest
potenti
use
merscov
antigen
carrier
inactiv
wholeviru
compris
entir
diseas
caus
virion
inactiv
physic
heat
chemic
iwv
offer
sever
advantag
includ
rel
low
cost
product
good
safeti
profil
involv
labori
genet
manipul
dezur
et
al
nevertheless
product
iwv
requir
live
viru
grown
highlevel
contain
antigen
immunogen
could
alter
viral
inactiv
step
dezur
et
al
formaldehydeinactivatedmerscov
induc
neutral
antibodi
mice
tcell
respons
supplement
iwv
combin
adjuv
alum
cpg
odn
report
enhanc
protect
immun
merscov
mice
transduc
hand
inactiv
bival
whole
viru
vaccin
target
rabi
viru
rabv
merscov
recent
develop
use
recombin
vector
encod
fusion
protein
compris
merscov
domain
fuse
cterminu
rabv
g
protein
follow
express
domain
incorpor
rabv
particl
mice
immun
chemic
inactiv
robust
neutral
antibodi
respons
g
protein
detect
inactiv
also
protect
merscov
challeng
wirblich
et
al
despit
benefit
associ
iwvbas
vaccin
inactiv
merscov
vaccin
report
potenti
caus
hypersensitivitytyp
lung
immunopatholog
reaction
upon
merscov
challeng
even
though
induc
neutral
antibodi
reduc
viral
load
transgen
mice
similar
observ
sarscov
agraw
et
al
live
attenu
vaccin
one
effect
vaccin
due
capabl
induc
immun
similar
natur
infect
vaccin
contain
viabl
attenu
viru
common
approach
develop
live
attenu
vaccin
includ
delet
viral
gene
confer
virul
via
revers
genet
gener
live
attenu
vaccin
highli
immunogen
thu
requir
adjuv
optim
efficaci
singl
immun
usual
suffici
induc
protect
immun
nevertheless
live
attenu
vaccin
come
unwant
limit
particularli
risk
revers
virul
strain
absolut
need
vaccin
cold
chain
live
attenu
vaccin
also
suitabl
infant
immunocompromis
individu
elderli
peopl
laur
et
al
live
attenu
vaccin
merscov
previous
develop
delet
e
gene
merscov
rmerscov
engin
viru
lack
infect
replic
singl
cycl
vaccin
base
live
attenu
virus
could
pose
biosafeti
problem
associ
risk
virul
revers
wherea
rmerscov
propag
defect
absenc
e
protein
prevent
straightforward
revers
virul
thu
provid
safer
altern
almazan
et
al
recent
live
attenu
merscov
gener
mutat
attenu
viru
protect
mice
mouseadapt
merscov
challeng
menacheri
et
al
merscov
replic
compet
recombin
measl
viru
mv
use
platform
develop
live
attenu
merscov
vaccin
recombin
mv
engin
express
fulllength
protein
mv
cov
truncat
version
mv
covsol
mv
cov
mv
covsol
shown
induc
neutral
antibodi
cellmedi
immun
respons
mv
merscov
protect
merscov
challeng
malczyk
et
al
three
year
later
bodmer
et
al
compar
mv
cov
uvinactiv
deriv
show
inactiv
version
induc
specif
immun
respons
mv
merscov
concurr
bodmer
et
al
construct
live
attenu
recombin
mv
express
merscov
n
protein
mv
mersn
administr
ifnar
mice
genet
modifi
mice
defici
type
ifn
receptor
transgen
express
human
induc
nspecif
cell
respons
although
strong
mv
cov
similarli
anoth
studi
viabl
recombin
vesicular
stomat
viru
vsv
g
protein
replac
protein
merscov
also
elicit
humor
cellmedi
immun
rhesu
macaqu
develop
mer
vaccin
start
immedi
follow
discoveri
merscov
preclin
trial
anim
model
capabl
recapitul
clinic
sign
symptom
human
must
prior
clinic
trial
licens
vaccin
gerdt
et
al
choic
anim
model
gener
prefer
phylogenet
closer
possibl
human
swearengen
therefor
major
vaccin
candid
evalu
nonhuman
primat
chimpanze
rhesu
macaqu
sibal
samson
marmoset
carrion
patterson
employ
anim
model
experi
howev
extrem
costli
gerdt
et
al
involv
nonhuman
primat
vaccin
evalu
strong
justif
support
evid
vitro
analysi
prefer
anim
studi
small
rodent
often
requir
gerdt
et
al
howev
merscov
infect
smaller
rodent
natur
repres
huge
challeng
initi
vaccin
develop
goldstein
weiss
although
transgen
mous
model
evalu
merscov
vaccin
success
develop
cost
transgen
anim
afford
mani
research
group
especi
less
affluent
part
world
issu
consequ
delay
develop
effect
vaccin
advanc
clinic
trial
fund
primari
driver
vaccin
develop
mani
vaccin
demonstr
promis
result
preclin
stage
requir
addit
invest
govern
privat
industri
advanc
clinic
trial
hakoum
et
al
howev
govern
fund
clinic
trial
rather
restrict
wherea
privat
industri
gener
profit
orient
market
size
potenti
profit
prioriti
smith
unlik
widespread
diseas
hepat
influenza
mer
case
primarili
report
saudi
arabia
apart
korea
outbreak
gossner
et
al
rel
low
occurr
like
limit
market
size
mer
vaccin
lead
lower
interest
privat
fund
bodi
although
three
potenti
mer
vaccin
candid
advanc
clinic
trial
current
phase
iii
complet
entir
trial
often
take
year
unlik
commerci
avail
come
year
despit
low
occurr
record
humantohuman
transmiss
recent
mer
outbreak
south
korea
demonstr
viru
emerg
second
third
gener
contact
reignit
public
awar
regard
danger
merscov
effect
treatment
mer
current
avail
therefor
best
solut
develop
function
mer
vaccin
prevent
merscov
infect
amongst
six
type
vaccin
discuss
studi
focus
viral
vectorbas
subunit
vaccin
even
though
mani
promis
vaccin
candid
propos
report
three
potenti
merscov
vaccin
candid
progress
phase
clinic
trial
dna
vaccin
two
viral
vectorbas
vaccin
mvamerss
still
like
mer
vaccin
avail
market
human
near
futur
therefor
consider
effort
given
minim
delay
execut
clinic
trial
better
understand
coordin
sponsor
primari
investig
investig
particip
stakehold
cy
ho
wrote
manuscript
sy
kh
wt
review
edit
approv
final
version
